Arimoclomol Side Effects
Medically reviewed by Drugs.com. Last updated on Nov 10, 2024.
Applies to arimoclomol: oral capsules.
Side effects include:
Most common adverse reactions (≥15%): upper respiratory tract infection, diarrhea, and decreased weight.
For healthcare professionals
Applies to arimoclomol: oral capsule.
General adverse events
The most common adverse reactions associated with this drug in combination with miglustat were upper respiratory tract infection, diarrhea, and decreased weight.[Ref]
Dermatologic
- Very common (10% or more): Urticaria (12%)
- Common (1% to 10%): Angioedema, progressive urticaria
Urticaria included 1 patient (3%) who reported urticaria alone and 2 patients (6%) who reported both urticaria and angioedema. The reactions occurred within the first 2 months of therapy.
Gastrointestinal
- Very common (10% or more): Diarrhea (23%)
Hematologic
- Frequency not reported: Thrombocytopenia
Thrombocytopenia was present at baseline in 2 patients and persisted throughout the trial. In 1 patient, thrombocytopenia developed and resolved during the trial.
Hypersensitivity
- Frequency not reported: Hypersensitivity reactions
Hypersensitivity reactions included urticaria and angioedema.
Metabolic
- Very common (10% or more): Decreased appetite (12%)
Nervous system
- Very common (10% or more): Tremor (12%), headache (12%), seizure (12%)
Other
- Very common (10% or more): Decreased weight (15%)
Decreased weight occurred in 4 patients and resolved in 3 patients. The mean duration of decreased weight was 33 days and ranged from 22 to 60 days. In 1 patient, 2 separate instances of weight loss occurred during the trial, lasting 22 and 24 days, respectively. The mean weight loss was about 6% from baseline in all patients; use of this drug was not interrupted in any patient.
Renal
- Frequency not reported: Increased serum creatinine
Across clinical trials in patients with Niemann-Pick disease type C, healthy subjects, and patients with other diseases, serum creatinine increased about 10% to 20% compared to baseline; these increases mainly occurred during the first month of therapy, were not associated with changes in glomerular function, and were reversible upon discontinuation of therapy.
Respiratory
- Very common (10% or more): Upper respiratory tract infection (31%), lower respiratory tract infection (12%)
Upper respiratory tract infection included upper respiratory tract infection and rhinitis.
See also:
Miplyffa
Miplyffa (arimoclomol) is a medication for Niemann-Pick disease type C (NPC) to help stop disease ...
Aqneursa
Aqneursa information from Drugs.com, includes Aqneursa side effects, interactions and indications.
Levacetylleucine
Levacetylleucine systemic is used for niemann-pick disease
References
1. (2024) "Product Information. Miplyffa (arimoclomol)." Zevra Therapeutics, Inc.
More about arimoclomol
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Arimoclomol side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.